-
Aug 9, 2023 Voluntary Recall of seven ( 7 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard)
-
Aug 9, 2023 Voluntary Recall of three ( 3 ) lots of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP)
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
-
Feb 1, 2023 Voluntary Recall of one ( 1 ) lot of APO-AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg - Lot PY1904
-
Dec 16, 2022 Accessa becomes the patient support program manager for Apotex Inc.'s Apo-Deferasirox™ and Apo-Deferasirox (Type J)™ products.
-
Sep 28, 2022 SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals
-
Jul 27, 2022 Voluntary Recall of four ( 4 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg
-
Jul 20, 2022 First Generic Alternative to Eliquis® Now Available in Canada
-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 26, 2022 Voluntary Recall of five ( 5 ) lots of APO-ACYCLOVIR (Acyclovir Tablets Apotex Standard) 200 mg and 800 mg.
-
Jan 19, 2022 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1832.
-
Nov 30, 2021 Canada-Wide Contest Recognizes the Impact of Pharmacy Professionals on Patient Care
-
Nov 9, 2021 Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada
-
Sep 30, 2021 VOLUNTARY NATIONWIDE RECALL: ONE LOT OF Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) 0.150 mg / 0.030 mg DUE TO POSSIBILITY OF ONE PLACEBO PILL IN PLACE OF AN ACTIVE PILL
-
Sep 27, 2021 Canadian Cancer Patients Have New Affordable Treatment Option
-
Sep 1, 2021 CANADIAN-MADE GENERIC OPTION TO TREAT MULTIPLE MYELOMA NOW AVAILABLE
-
Apr 29, 2021 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1831.
-
Apr 15, 2021 GOVERNMENT OF CANADA AWARDS APOTEX INC. A SIGNIFICANT CONTRACT TO SUPPLY A SAFETY NET OF ADDITIONAL DEXAMETHASONE IN CANADA
-
Apr 13, 2021 Voluntary Recall of one ( 1 ) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot RF0410.
-
Jun 12, 2020 Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 23, 2025
Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
Toronto, ON - October 23, 2025 - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based pharmaceutical company, today announced that Health Canada has granted a Notice of Compliance (NOC) for LOQTORZI® (toripalimab) for the treatment of nasopharyngeal carcinoma (NPC), an ultra-rare and aggressive cancer.
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.